Payment overview · 2025
General Payments
$494.84
16 reported records · 7 companies
Healthcare provider profile · identity verified
Esau Laurencin, MD
Allopathic & Osteopathic Physicians|General Practice · LONGWOOD, FL · NPI 1588075774
Verified facts
What the public records show
CMS Open Payments records show Esau Laurencin, MD received $494.84 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $187.24 | 37.8% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $126.46 | 25.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.52 | 10.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.89 | 9.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $44.52 | 9.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.16 | 3.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.05 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $494.84 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $142.64 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $126.46 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $51.52 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $44.60 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $44.52 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
61 | 26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 559 | 244 |
| Amlodipine Besylate | Amlodipine Besylate | 407 | 159 |
| Losartan Potassium | Losartan Potassium | 260 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 109 |
| Furosemide | Furosemide | 237 | 105 |
| Lisinopril | Lisinopril | 207 | 99 |
| Gabapentin | Gabapentin | 203 | 92 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 182 | 79 |
| Carvedilol | Carvedilol | 180 | 70 |
| Metformin Hcl | Metformin Hcl | 176 | 81 |
| Azithromycin | Azithromycin | 166 | 94 |
| Omeprazole | Omeprazole | 141 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 121 | 63 |
| Eliquis | Apixaban | 119 | 44 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 118 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 52 |
| Ibuprofen | Ibuprofen | 112 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 48 |
| Allopurinol | Allopurinol | 107 | 39 |
| Prednisone | Prednisone | 99 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 37 |
| Potassium Chloride | Potassium Chloride | 91 | 38 |
| Methylprednisolone | Methylprednisolone | 78 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 25 |
| Montelukast Sodium | Montelukast Sodium | 64 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 26 |
| Alendronate Sodium | Alendronate Sodium | 62 | 29 |
| Symbicort | Budesonide/Formoterol Fumarate | 61 | 26 |
| Meloxicam | Meloxicam | 59 | 23 |
| Spironolactone | Spironolactone | 57 | 25 |
| Ozempic | Semaglutide | 56 | 18 |
| Baclofen | Baclofen | 55 | 34 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 27 |
| Ibu | Ibuprofen | 49 | 14 |
| Chlorthalidone | Chlorthalidone | 48 | 20 |
| Famotidine | Famotidine | 48 | 21 |
| Tramadol Hcl | Tramadol Hcl | 48 | 23 |
| Warfarin Sodium | Warfarin Sodium | 48 | 15 |
| Trazodone Hcl | Trazodone Hcl | 47 | 27 |
| Sertraline Hcl | Sertraline Hcl | 41 | 18 |
| Glipizide | Glipizide | 40 | 16 |
| Methocarbamol | Methocarbamol | 40 | 19 |
| Nifedipine Er | Nifedipine | 35 | 11 |
| Simvastatin | Simvastatin | 34 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 14 |
| Meclizine Hcl | Meclizine Hcl | 33 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | 11 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 17 |
| Glimepiride | Glimepiride | 30 | 12 |
| Levetiracetam | Levetiracetam | 30 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | 15 |
| Donepezil Hcl | Donepezil Hcl | 28 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | 11 |
| Terazosin Hcl | Terazosin Hcl | 27 | 12 |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 22 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | 13 |
| Alprazolam | Alprazolam | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | 13 |
| Varenicline Tartrate | Varenicline Tartrate | 20 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 17 |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | 13 |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Mupirocin | Mupirocin | 14 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $494.84 · 16 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, GEMTESA, JARDIANCE, Korlym | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error